Persistent infection with human papillomavirus (HPV) is a key factor in the
development of precancerous lesions and invasive cervical cancer. Prophylactic
vaccines are an effective approach to reduce HPV-related disease burden. Regarding
the studies, at least 110-120 countries have implemented Cervarix™ and Gardasil™ for
induction of protective effects against HPV infections. On the other hand, several
clinical trials are underway for therapeutic HPV vaccination. Special approaches is
considered to increase the potency of therapeutic vaccines including the use of
effective adjuvant, selection of strong immunogen and combination therapies to
overcome tumor immune suppression. In this chapter, we will summarize main
preventive and therapeutic HPV vaccines in preclinical and clinical trials.
Keywords: Clinical study, HPV infection, Preclinical study, Prophylactic
vaccine, Therapeutic vaccine.Clinical study, HPV infection, Preclinical study, Prophylactic
vaccine, Therapeutic vaccine.
